Cytostatic treatment of glomerular diseases. II. Effect of azathioprine on serum and urine proteins. Report from a Copenhagen Study Group of Renal Diseases.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000419:Albuminuria; D001379:Azathioprine / Q000627:therapeutic use*; D001798:Blood Proteins / Q000378:metabolism*; D002648:Child; D002675:Child, Preschool; D005260:Female; D005921:Glomerulonephritis / Q000188:drug therapy; D006801:Humans; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D007674:Kidney Diseases / Q000097:blood / Q000188:drug therapy* / Q000652:urine; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000652:urine; D008259:Macroglobulins; D008297:Male; D008875:Middle Aged; D009404:Nephrotic Syndrome / Q000188:drug therapy; D011507:Proteinuria; D012709:Serum Albumin / Q000378:metabolism; D012712:Serum Globulins / Q000378:metabolism; D014168:Transferrin
D001798:Blood Proteins; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D008259:Macroglobulins; D012709:Serum Albumin; D012712:Serum Globulins; D014168:Transferrin; D001379:Azathioprine